Skip to main content
News Schultze 06.2021
Prof. Joachim Schultze, Director of Systems Medicine at the DZNE and professor at the Life & Medical Sciences Institute (LIMES) at the University of Bonn
© Frommann / DZNE

News categories: Publication

AI with swarm intelligence

Novel technology for cooperative analysis of big data

Communities benefit from sharing knowledge and experience among their members. Following a similar principle - called "swarm learning" - an international research team has trained artificial intelligence algorithms to detect blood cancer, lung diseases and COVID-19 in data stored in a decentralized fashion. ImmunoSensation2 member Prof. Joachim Schultze from the DZNE and LIMES Institute is lead author of the study, recently published in Nature.

This approach has advantage over conventional methods since it inherently provides privacy preservation technologies, which facilitates cross-site analysis of scientific data. Swarm learning could thus significantly promote and accelerate collaboration and information exchange in research, especially in the field of medicine. Experts from the DZNE, the University of Bonn, the information technology company Hewlett Packard Enterprise (HPE) and other research institutions report on this in the scientific journal "Nature".

Analyzing the resulting volumes of information - known as "big data" - is considered a key to better treatment options. "Medical research data are a treasure. They can play a decisive role in developing personalized therapies that are tailored to each individual more precisely than conventional treatments," said Joachim Schultze, Director of Systems Medicine at the DZNE and professor at the Life & Medical Sciences Institute (LIMES) at the University of Bonn.

"It's critical for science to be able to use such data as comprehensively and from as many sources as possible." However, the exchange of medical research data across different locations or even between countries is subject to data protection and data sovereignty regulations. In practice, these requirements can usually only be implemented with significant effort. In addition, there are technical barriers: For example, when huge amounts of data have to be transferred digitally, data lines can quickly reach their performance limits. In view of these conditions, many medical studies are locally confined and cannot utilize data that is available elsewhere.

In light of this, a research collaboration led by Joachim Schultze tested a novel approach for evaluating research data stored in a decentralized fashion. The basis for this was the still young "Swarm Learning" technology developed by HPE. In addition to the IT company, numerous research institutions from Greece, the Netherlands and Germany - including members of the "German COVID-19 OMICS Initiative" (DeCOI) - participated in this study.

Only algorithms and parameters are shared - in a sense, lessons learned. "Swarm Learning fulfills the requirements of data protection in a natural way," Joachim Schultze emphasized. Unlike "federated learning", in which the data also remains locally, there is no centralized command center, the Bonn scientist explained. "Swarm Learning happens in a cooperative way based on rules that all partners have agreed on in advance. This set of rules is captured in a blockchain."

The researchers are now providing practical proof of this approach through the analysis of X-ray images of the lungs and of transcriptomes: The latter are data on the gene activity of cells. In the current study, the focus was specifically on immune cells circulating in the blood - in other words, white blood cells. "Data on the gene activity of blood cells are like a molecular fingerprint. They hold important information about how the organism reacts to a disease," Schultze said. "Transcriptomes are available in large numbers just like X-ray images, and they are highly complex. This is exactly the kind of information you need for artificial intelligence analysis. Such data is perfect for testing Swarm Learning."

The research team addressed a total of four infectious and non-infectious diseases: two variants of blood cancer (acute myeloid leukemia and acute lymphoblastic leukemia), as well as tuberculosis and COVID-19. The data included a total of more than 16,000 transcriptomes.

The current study was just a test run. In the future, we intend to apply this technology to Alzheimer's and other neurodegenerative diseases," Schultze said. "Swarm Learning has the potential to be a real game changer and could help make the wealth of experience in medicine more accessible worldwide. Not only research institutions but also hospitals, for example, could join together to form such swarms and thus share information for mutual benefit."

Publication

S. Warnat-Herresthal et al.: Swarm Learning for decentralized and confidential clinical machine learning. Nature


Contact

Prof. Dr. Joachim L. Schultze

German Center for Neurodegenerative Diseases

LIMES Institute at the University of Bonn

Phone: +49 228 43302-410

Email: joachim.schultze@dzne.de

Related news

News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview